-
1 Comment
ReproCELL Incorporated is currently in a long term downtrend where the price is trading 20.0% below its 200 day moving average.
From a valuation standpoint, the stock is 98.2% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 23.2.
ReproCELL Incorporated's total revenue rose by 2.3% to $334M since the same quarter in the previous year.
Its net income has dropped by 28.3% to $-292M since the same quarter in the previous year.
Based on the above factors, ReproCELL Incorporated gets an overall score of 2/5.
Exchange | F |
---|---|
CurrencyCode | EUR |
ISIN | JP3974770004 |
Sector | Healthcare |
Industry | Biotechnology |
Beta | 0.79 |
---|---|
Market Cap | 81M |
PE Ratio | None |
Target Price | None |
Dividend Yield | None |
ReproCELL Incorporated provides stem cell research and drug discovery services in Japan. It offers stem cell reagents, including RNA reprogramming, small molecules, growth factors and cytokines, antibodies and staining kits, cell substrates, cryopreservation media, dissociation solution, and transfection reagents; differentiated induced pluripotent stem cell (iPSC) and related reagents, feeder cells, pluripotent stem cells, and synfire induced neurons; 3D cell culture; and labware. The company also provides research stem cell, genomics, clinical stem cell research, preclinical and drug discovery CRO, precision medicine, human tissue samples, clinical laboratory, diagnostic, and gene editing services. ReproCELL Incorporated was incorporated in 2003 and is based in Yokohama, Japan.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 6RC.F using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025